Home  /  Resource Library  /  Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Waldenstrom Macroglobulinemia from a Phase 2 Trial

Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Waldenstrom Macroglobulinemia from a Phase 2 Trial

ASH 2020: Results of a phase II trial examining zanubrutinib for treatment of relapsed Waldenstrom Macroglobulinemia.